Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 11:38AM ET
2.92
Dollar change
+0.15
Percentage change
5.42
%
IndexRUT P/E- EPS (ttm)-0.51 Insider Own54.48% Shs Outstand125.07M Perf Week5.80%
Market Cap365.29M Forward P/E- EPS next Y-0.83 Insider Trans0.07% Shs Float56.94M Perf Month4.29%
Income-63.67M PEG- EPS next Q-0.16 Inst Own28.90% Short Float2.17% Perf Quarter-13.86%
Sales0.00M P/S- EPS this Y-45.10% Inst Trans-1.76% Short Ratio14.60 Perf Half Y-9.03%
Book/sh2.12 P/B1.38 EPS next Y-11.82% ROA-19.42% Short Interest1.23M Perf Year8.96%
Cash/sh1.39 P/C2.11 EPS next 5Y- ROE-21.95% 52W Range2.16 - 4.65 Perf YTD-2.34%
Dividend Est.- P/FCF- EPS past 5Y- ROI-21.48% 52W High-37.20% Beta0.99
Dividend TTM- Quick Ratio19.39 Sales past 5Y0.00% Gross Margin- 52W Low35.19% ATR (14)0.19
Dividend Ex-Date- Current Ratio19.39 EPS Y/Y TTM-9.74% Oper. Margin0.00% RSI (14)57.27 Volatility4.72% 7.70%
Employees167 Debt/Eq0.13 Sales Y/Y TTM- Profit Margin- Recom2.00 Target Price4.25
Option/ShortYes / Yes LT Debt/Eq0.12 EPS Q/Q-26.82% Payout- Rel Volume1.34 Prev Close2.77
Sales Surprise- EPS Surprise11.11% Sales Q/Q- EarningsFeb 28 BMO Avg Volume84.45K Price2.92
SMA209.47% SMA504.76% SMA200-3.90% Trades Volume41,195 Change5.42%
Date Action Analyst Rating Change Price Target Change
Jan-06-22Initiated Morgan Stanley Equal-Weight $8
Nov-02-21Initiated Cowen Outperform
Aug-04-21Initiated Goldman Neutral $10
Jul-13-21Initiated Jefferies Buy $13
Feb-28-24 08:00AM
07:36AM
Feb-22-24 08:00AM
Feb-07-24 08:00AM
Nov-30-23 08:00AM
08:05AM Loading…
Nov-01-23 08:05AM
Oct-31-23 08:05AM
Oct-11-23 08:05AM
Sep-06-23 07:30AM
Aug-04-23 08:00AM
Aug-02-23 07:30AM
Jul-11-23 09:23AM
May-24-23 08:05AM
May-02-23 06:30AM
Apr-18-23 04:05PM
08:00AM Loading…
Mar-23-23 08:00AM
Mar-07-23 08:00AM
Feb-23-23 06:05AM
Feb-21-23 08:00AM
Jan-26-23 08:00AM
07:45AM
Jan-19-23 08:00AM
Nov-16-22 08:00AM
Nov-01-22 06:05AM
Oct-05-22 08:00AM
Sep-23-22 08:00AM
Sep-01-22 08:00AM
Aug-30-22 08:00AM
Aug-11-22 06:30AM
Aug-02-22 06:48AM
04:05PM Loading…
Aug-01-22 04:05PM
Jul-13-22 08:00AM
May-12-22 06:28AM
May-03-22 06:00AM
Apr-12-22 08:00AM
Apr-07-22 08:00AM
Apr-04-22 08:00AM
Mar-31-22 04:05PM
Mar-05-22 07:22AM
Feb-24-22 06:00AM
Feb-16-22 04:05PM
Feb-02-22 01:38PM
Jan-27-22 08:00AM
Dec-16-21 01:07PM
Dec-05-21 06:39AM
Nov-02-21 08:00AM
06:00AM
Oct-11-21 08:00AM
Sep-10-21 10:21AM
Sep-03-21 09:00AM
Aug-10-21 06:00AM
Aug-09-21 08:00AM
Jul-13-21 08:00AM
Jun-17-21 07:00AM
Nautilus Biotechnology, Inc. is a life sciences company, which engages in the development of a proteomics platform for analyzing and quantifying the human proteome. Its products include Proteome Analysis System, Reagent Kits, and Software and Analysis. The company was founded by Sujal Patel and Parag Mallick in 2016 and is headquartered in Seattle, WA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Patel Sujal MCEO, President, and SecretaryMar 11 '24Buy2.8412,04434,21610,064,488Mar 11 08:21 PM
Patel Sujal MCEO, President, and SecretaryMar 08 '24Buy2.992,4307,26210,052,444Mar 11 08:21 PM
Patel Sujal MCEO, President, and SecretaryMar 07 '24Buy2.8918,85454,42410,050,014Mar 07 07:06 PM
Patel Sujal MCEO, President, and SecretaryMar 06 '24Buy2.709,26725,03410,031,160Mar 07 07:06 PM
Patel Sujal MCEO, President, and SecretaryMar 05 '24Buy2.657,40519,59710,021,893Mar 07 07:06 PM